Deutsche Bank downgrades Novo Nordisk to Sell; China accepts oral Wegovy application
NVO Novo Nordisk ADR
$46.26 -1.97%
View chart & analysis → - 1Deutsche Bank downgrades its rating on Novo Nordisk (NVO) from Hold to Sell
- 2Price target cut from 290 to 265 Danish kroner, implying 10% downside; revenue seen largely flat from 2025–27
- 3China has accepted the oral Wegovy application, but competition with Eli Lilly (LLY) and the broader market is inevitable
This 3-line summary is compiled from the report below.
Stocktwits +1 View original ↗
오늘의 AI 픽 5종목, 무료로 전부 공개합니다숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다